516 related articles for article (PubMed ID: 11600818)
21. Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis.
Lin B; Zhao K; Yang D; Bai D; Liao Y; Zhou Y; Yu Z; Yu X; Guo Q; Lu N
J Cell Physiol; 2019 Feb; 234(2):1913-1924. PubMed ID: 30105796
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome.
Albitar M
Acta Haematol; 2001; 106(4):170-6. PubMed ID: 11815714
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis in hematologic malignancies.
Moehler TM; Neben K; Ho AD; Goldschmidt H
Ann Hematol; 2001 Dec; 80(12):695-705. PubMed ID: 11797109
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
25. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.
Negaard HF; Iversen N; Bowitz-Lothe IM; Sandset PM; Steinsvik B; Ostenstad B; Iversen PO
Leukemia; 2009 Jan; 23(1):162-9. PubMed ID: 18800145
[TBL] [Abstract][Full Text] [Related]
26. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Giles FJ; Stopeck AT; Silverman LR; Lancet JE; Cooper MA; Hannah AL; Cherrington JM; O'Farrell AM; Yuen HA; Louie SG; Hong W; Cortes JE; Verstovsek S; Albitar M; O'Brien SM; Kantarjian HM; Karp JE
Blood; 2003 Aug; 102(3):795-801. PubMed ID: 12649163
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
[TBL] [Abstract][Full Text] [Related]
28. Anti-angiogenic activity of the purine analog 6-thioguanine.
Presta M; Belleri M; Vacca A; Ribatti D
Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
[TBL] [Abstract][Full Text] [Related]
29. Targeting the vascular endothelial growth factor in hematologic malignancies.
Paesler J; Gehrke I; Poll-Wolbeck SJ; Kreuzer KA
Eur J Haematol; 2012 Nov; 89(5):373-84. PubMed ID: 22928557
[TBL] [Abstract][Full Text] [Related]
30. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia.
Litwin C; Leong KG; Zapf R; Sutherland H; Naiman SC; Karsan A
Am J Hematol; 2002 May; 70(1):22-30. PubMed ID: 11994978
[TBL] [Abstract][Full Text] [Related]
31. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
32. The emerging role of angiogenesis inhibitors in hematologic malignancies.
Giles FJ
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):23-9. PubMed ID: 12102577
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.
Loges S; Tinnefeld H; Metzner A; Jücker M; Butzal M; Bruweleit M; Fischer U; Draab E; Schuch G; O'-Farrel AM; Hossfeld DK; Bokemeyer C; Fiedler W
Leuk Lymphoma; 2006 Dec; 47(12):2601-9. PubMed ID: 17169805
[TBL] [Abstract][Full Text] [Related]
34. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.
Eleutherakis-Papaiakovou V; Karali M; Kokkonouzis I; Tiliakos I; Dimopoulos MA
Leuk Lymphoma; 2003 Jun; 44(6):937-48. PubMed ID: 12854891
[TBL] [Abstract][Full Text] [Related]
36. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV
Leukemia; 2004 Mar; 18(3):624-7. PubMed ID: 14749707
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis in hematologic malignancies and its clinical implications.
Yang R; Han ZC
Int J Hematol; 2002 Apr; 75(3):246-56. PubMed ID: 11999351
[TBL] [Abstract][Full Text] [Related]
38. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.
Perez-Atayde AR; Sallan SE; Tedrow U; Connors S; Allred E; Folkman J
Am J Pathol; 1997 Mar; 150(3):815-21. PubMed ID: 9060819
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies.
Kessler T; Fehrmann F; Bieker R; Berdel WE; Mesters RM
Curr Drug Targets; 2007 Feb; 8(2):257-68. PubMed ID: 17305503
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
